Header Logo

Connection

Fernando Martinez to Cardiovascular Diseases

Back to Details
This is a "connection" page, showing publications Fernando Martinez has written about Cardiovascular Diseases.
Fernando Martinez
Connection Strength
2.204
Cardiovascular Diseases
  1. Singh D, Roche N, Halpin D, Agusti A, Wedzicha JA, Martinez FJ. Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2016 09 01; 194(5):541-9.
    View in: PubMed
    Score: 0.313
  2. Dransfield MT, Cockcroft JR, Townsend RR, Coxson HO, Sharma SS, Rubin DB, Emmett AH, Cicale MJ, Crater GD, Martinez FJ. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. Respir Med. 2011 Sep; 105(9):1322-30.
    View in: PubMed
    Score: 0.218
  3. Wade RC, Martinez FJ, Criner GJ, Tombs L, Lipson DA, Halpin DMG, Han MK, Singh D, Wise RA, Kalhan R, Dransfield MT. ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD. Eur Respir J. 2025 Feb; 65(2).
    View in: PubMed
    Score: 0.140
  4. Singh D, Martinez FJ, Hurst JR, Han MK, Gale CP, Fredriksson M, Kisielewicz D, Mushunje A, Movitz C, Ojili N, Parikh H, Arya N, Bowen K, Patel M. Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS). Am J Respir Crit Care Med. 2025 Feb; 211(2):205-214.
    View in: PubMed
    Score: 0.140
  5. Krishnan JK, Murphy ML, Edgar AS, Aronson KI, Guri A, Gross L, Younger T, Martinez FJ, Safford MM. Perspectives of Black Adults Living with Chronic Obstructive Pulmonary Disease on Barriers to Cardiovascular Disease Prevention. Ann Am Thorac Soc. 2024 May; 21(5):706-715.
    View in: PubMed
    Score: 0.133
  6. Krishnan JK, Rajan M, Banerjee S, Mallya SG, Han MK, Mannino DM, Martinez FJ, Safford MM. Race and Sex Differences in Mortality in Individuals with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2022 10; 19(10):1661-1668.
    View in: PubMed
    Score: 0.119
  7. Dransfield MT, Criner GJ, Halpin DMG, Han MK, Hartley B, Kalhan R, Lange P, Lipson DA, Martinez FJ, Midwinter D, Singh D, Wise R, Kunisaki KM. Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial. J Am Heart Assoc. 2022 09 20; 11(18):e024350.
    View in: PubMed
    Score: 0.119
  8. Bikov A, Lange P, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Dixon IJ, Martinez FJ, Newby DE, Yates JC, Vestbo J. FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease. Int J Chron Obstruct Pulmon Dis. 2020; 15:1135-1142.
    View in: PubMed
    Score: 0.101
  9. Adamson PD, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Dixon IJ, Martinez FJ, Newby DE, Vestbo J, Yates JC, Mills NL. Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary?Disease. J Am Coll Cardiol. 2018 09 04; 72(10):1126-1137.
    View in: PubMed
    Score: 0.090
  10. Celli B, Anderson JA, Brook R, Calverley P, Crim C, Holmes AP, Martinez FJ, Newby DE, Yates J, Vestbo J. Long-Acting ?-Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. Am J Respir Crit Care Med. 2018 06 15; 197(12):1641-1644.
    View in: PubMed
    Score: 0.089
  11. Dransfield MT, McAllister DA, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Gallot N, Martinez FJ, Scanlon PD, Yates J, Vestbo J, Newby DE. ?-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. Ann Am Thorac Soc. 2018 05; 15(5):608-614.
    View in: PubMed
    Score: 0.088
  12. Calverley PMA, Anderson JA, Brook RD, Crim C, Gallot N, Kilbride S, Martinez FJ, Yates J, Newby DE, Vestbo J, Wise R, Celli BR. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. Am J Respir Crit Care Med. 2018 01 01; 197(1):47-55.
    View in: PubMed
    Score: 0.086
  13. Brook RD, Anderson JA, Calverley PM, Celli BR, Crim C, Denvir MA, Magder S, Martinez FJ, Rajagopalan S, Vestbo J, Yates J, Newby DE. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart. 2017 10; 103(19):1536-1542.
    View in: PubMed
    Score: 0.082
  14. Marrachelli VG, Rentero P, Mansego ML, Morales JM, Galan I, Pardo-Tendero M, Martinez F, Martin-Escudero JC, Briongos L, Chaves FJ, Redon J, Monleon D. Genomic and Metabolomic Profile Associated to Clustering of Cardio-Metabolic Risk Factors. PLoS One. 2016; 11(9):e0160656.
    View in: PubMed
    Score: 0.078
  15. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016 Apr 30; 387(10030):1817-26.
    View in: PubMed
    Score: 0.076
  16. Pichler G, Martinez F, Redon J. Reply. J Hypertens. 2015 Dec; 33(12):2551.
    View in: PubMed
    Score: 0.074
  17. Pichler G, Martinez F, Vicente A, Solaz E, Calaforra O, Redon J. Carotid-femoral pulse wave velocity assessment by two different methods: implications for risk assessment. J Hypertens. 2015 Sep; 33(9):1868-75; discussion 1875.
    View in: PubMed
    Score: 0.073
  18. Mansego ML, Redon J, Martinez-Hervas S, Real JT, Martinez F, Blesa S, Gonzalez-Albert V, Saez GT, Carmena R, Chaves FJ. Different impacts of cardiovascular risk factors on oxidative stress. Int J Mol Sci. 2011; 12(9):6146-63.
    View in: PubMed
    Score: 0.056
  19. Kasela S, Ortega VE, Martorella M, Garudadri S, Nguyen J, Ampleford E, Pasanen A, Nerella S, Buschur KL, Barjaktarevic IZ, Barr RG, Bleecker ER, Bowler RP, Comellas AP, Cooper CB, Couper DJ, Criner GJ, Curtis JL, Han MK, Hansel NN, Hoffman EA, Kaner RJ, Krishnan JA, Martinez FJ, McDonald MN, Meyers DA, Paine R, Peters SP, Castro M, Denlinger LC, Erzurum SC, Fahy JV, Israel E, Jarjour NN, Levy BD, Li X, Moore WC, Wenzel SE, Zein J, Langelier C, Woodruff PG, Lappalainen T, Christenson SA. Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. Genome Med. 2021 Apr 21; 13(1):66.
    View in: PubMed
    Score: 0.027
  20. Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, Lomas DA, Martin N, Martinez FJ, Singh D, Wise R, Lipson DA. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respir Res. 2020 Jun 05; 21(1):139.
    View in: PubMed
    Score: 0.025
  21. Crim C, Anderson JA, Calverley PMA, Celli BR, Cowans NJ, Martinez FJ, Newby DE, Vestbo J, Yates JC, Brook RD. Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-Blind Clinical Trial. Am J Respir Crit Care Med. 2020 05 15; 201(10):1307-1310.
    View in: PubMed
    Score: 0.025
  22. Byrd JB, Newby DE, Anderson JA, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez FJ, Vestbo J, Yates J, Brook RD. Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. Eur Heart J. 2018 09 01; 39(33):3128-3134.
    View in: PubMed
    Score: 0.022
  23. Vestbo J, Anderson J, Brook RD, Calverley PM, Celli BR, Crim C, Haumann B, Martinez FJ, Yates J, Newby DE. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J. 2013 May; 41(5):1017-22.
    View in: PubMed
    Score: 0.015
  24. Redon J, Martinez F, Cheung AK. Special considerations for antihypertensive agents in dialysis patients. Blood Purif. 2010; 29(2):93-8.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.